Chabner Colloquium: Answering the Big Questions in Cancer Research & 2018 STO Annual MeetingAbstract 1 – Beyond PARP1: Ribosylation as a Target for Cancer TherapyAbstract 2 – Melanoma: Clues to Improved Therapeutic Efficacy from Disease PathogenesisAbstract 3 – Targeting Cell Death Pathways with Precision Using Functional AssaysAbstract 4 – Digital RNA‐based Analysis of Circulating Tumor Cells for Noninvasive Monitoring of CancerAbstract 5 – Clinical Application of Liquid Biopsies and Genotype‐Directed Targeted Therapies for Metastatic Breast CancerAbstract 6 – Microfluidics for the Characterization of Tumor‐Specific Extracellular VesiclesAbstract 7 – CAR T‐Cell Therapy for Ovarian CancerAbstract 8 – Molecular Tumor Board: Resistance to Checkpoint InhibitorsAbstract 9 – Dissecting Response and Resistance to Immune Checkpoint BlockadeAbstract 10 – The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast CancerAbstract 11 – Clinical Utility of Longitudinal Molecular Profiling for Management of ALK ‐Positive Lung CancerAbstract 12 – New Biomarkers in a Novel Antibody‐Drug Conjugate for Triple‐Negative Breast CancerAbstract 13 – LIN28B, a Promoter of Metastasis and Drug Resistance

• 期刊名称The Oncologist
• 作者Richon, Victoria; Fisher, David E.; Letai, Anthony; Haber, Daniel A.; Bardia, Aditya; Stott, Shannon; Yeku, Oladapo; Sullivan, Ryan; Liu, David; Spring, Laura; Dagogo‐Jack, Ibiayi; Nagayama, Aiko; Franses, Joseph
• 卷第23卷
• 印刷ISSN1083-7159
• 电子ISSN1549-490X
• 文件大小6073.51KB
• 发表时间2018-11
• DOI10.1634/theoncologist.2018-MA-1